With a suppressed TSH (0.1 µU/mL) and a T3 at the upper limit of normal (9.8 pmol/L), what is the appropriate treatment plan?

Treatment Plan for TSH 0.1 with T3 9.8

With a suppressed TSH of 0.1 mU/L and T3 at the upper limit of normal (9.8 pmol/L), you should strongly consider treatment if the patient is ≥65 years old, has cardiac risk factors/heart disease/osteoporosis, is a postmenopausal woman not on estrogens or bisphosphonates, or has hyperthyroid symptoms 1.

Initial Assessment Required

Before initiating treatment, you must:

• Confirm persistence: Repeat TSH measurement after 3-6 months to rule out transient causes (acute illness, medications, transient thyroiditis) 1
• Check free T4: The T3 value alone is insufficient—you need free T4 to determine if this is overt hyperthyroidism (elevated fT4) or subclinical hyperthyroidism (normal fT4) 1
• Identify the etiology: Obtain thyroid antibodies (TRAb, TPO), consider thyroid uptake scan if diagnosis unclear 1

Treatment Decision Algorithm

If TSH remains <0.1 mU/L persistently:

High-priority treatment groups (strong recommendation):

• Age ≥65 years
• Postmenopausal women not on estrogens/bisphosphonates
• Cardiac risk factors or established heart disease
• Osteoporosis
• Symptomatic hyperthyroidism (palpitations, tremor, weight loss, heat intolerance)

Consider treatment in younger patients (<65 years) if symptomatic 1

May observe without treatment in young, asymptomatic patients with no comorbidities, though continued monitoring is essential 1

If TSH is 0.1-0.4 mU/L (above your patient's level):

Treatment is less urgent but should still be considered in patients ≥65 years or those with cardiac disease/symptoms 1

Treatment Approach

Treatment should follow the same principles as overt hyperthyroidism based on the underlying etiology 1:

For Graves' Disease:

• Methimazole is preferred (except first trimester pregnancy) 1
• Radioactive iodine (RAI) is appropriate, especially in older patients
• Long-term antithyroid drugs are reasonable in younger patients with mild disease (higher remission rates) 1

For Toxic Multinodular Goiter:

• Radioactive iodine is the preferred treatment, particularly in elderly patients 1

Symptomatic Management:

• Beta-adrenergic blockade may be sufficient to control cardiovascular symptoms, especially atrial fibrillation risk, and can be used as sole therapy in select cases 1

Critical Pitfalls to Avoid

1. Don't treat without confirming persistence: A single suppressed TSH can occur with non-thyroidal illness, medications, or transient thyroiditis 1

2. Don't assume the diagnosis without free T4: Your patient's T3 is at the upper limit of normal, but without free T4, you cannot distinguish between subclinical and overt hyperthyroidism 1

3. Don't use antithyroid drugs in elderly patients before RAI without clear indication: The risks of antithyroid drug therapy may outweigh benefits of pretreatment in subclinical hyperthyroidism 1

4. Don't ignore age and comorbidities: The evidence for treatment benefit is strongest in patients ≥65 years with TSH <0.1 mU/L due to increased atrial fibrillation and bone loss risk 1

Monitoring Strategy

If you elect to observe rather than treat:

• Repeat thyroid function tests every 3-6 months
• Monitor for progression to overt hyperthyroidism (1-2% per year with TSH <0.1 mU/L) 2
• Assess for development of symptoms or cardiac complications
• Note that TSH may normalize spontaneously in some patients 2, 1

The key distinction here is that subclinical hyperthyroidism with TSH <0.1 mU/L carries meaningful cardiovascular and skeletal risks in older adults and those with comorbidities, making treatment a priority in these populations rather than a "wait and see" approach 1.